2.Crofts, N, et al. Minimising harm from hepatitis C virus needs better strategies. British Medical Journal 2000; 321: 899.
3.Kamili, S, et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infection Control and Hospital Epidemiology 2007; 28: 519–524.
4.Hagan, H, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 2001; 91: 42–46.
5.Lucidarme, D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology and Infection 2004; 132: 699–708.
6.De, P, et al. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. Journal of Viral Hepatitis 2008; 15: 279–292.
7.Tortu, S, et al. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Substance Use and Misuse 2004; 39: 211–224.
8.Martinez, A, Talal, AH. Noninjection drug use: an under-appreciated risk factor for hepatitis C virus transmission. Liver International 2008; 28: 757–760.
9.Micallef, JM, Kaldor, JM, Dore, GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006; 13: 34–41.
10.Lai, ME, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388–390.
11.Bowden, S, et al. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. Journal of Viral Hepatitis 2005; 12: 322–324.
12.Micallef, JM, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. Journal of Viral Hepatitis 2007; 14: 413–418.
13.Van De Laar, TJ, et al. Frequent HCV reinfection and superinjection in a cohort of injecting drug users in Amsterdam. Journal of Hepatology 2009; 51: 667–674.
14.Grebely, J, et al. Hepatitis C virus reinfection in injection drug users. Hepatology 2006; 44: 1139–1145.
15.Osburn, WO, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315–324.
16.Six, C, Hamers, F, Brunet, JB. HIV, HCV and HBV infections among drug users attending care centres with housing accommodations 1993–1998. Bulletin Epidémiologique Hebdomadaire 1999; 32: 1–4.
17.Bello, PY, et al. Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. European Journal of Clinical Microbiology and Infectious Diseases 1998; 17: 570–572.
18.Jauffret-Roustide, M, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infectious Diseases 2009; 9: 113.
19.Amin, J, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiology and Infection 2007; 135: 144–150.
21.Mathei, C, et al. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. Journal of Viral Hepatitis 2006; 13: 560–570.
22.Dubois, F, et al. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997; 25: 1490–1496.
23.Meffre, C, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology 2010; 82: 546–555.
24.Valenciano, M, Emmanuelli, J, Lert, F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction 2001; 96: 597–606.
26.Downs, AM, et al. Reconstruction and prediction of the HIV/AIDS epidemic amoung adults in the European Union and in the low prevalence countries of central and eastern Europe. AIDS 1997; 11: 649–662.
27.Deuffic, S, et al. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596–1601.
28.Di Nino, F, et al. Screening and treatment of hepatitis C by the microstructure medical network in Alsace, France, 2006–2007. Bulletin Epidémiologique Hebdomadaire 2009; 37: 4–8.
29.Lucidarme, D, et al. Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts. Gastroentérologie Clinique et Biologique 1994; 18: 964–968.
30.Chossegros, P. Management of drug addiction in France (a short history). Gastroentérologie Clinique et Biologique 2007; 31: S44–50.
32.Costes, JM. A prevalence estimate. In: Carpentier, C, Costes, JM, eds. Drogues et Toxicomanies: Indicateurs et Tendances, 1995, pp. 44–45.
33.Toufik, A, Escots, S, Cadet-Tairou, A. Change in drugs use linked to the diffusion of substitution treatments. Illicit drug uses in France since 1999, from the TREND system. French Observatory for Drugs and Drug Addiction (OFDT), 2010.
35.OFDT.Illicit drug use in France since 1999, from the TREND system. Costes JM (Dir.). French Observatory for Drugs and Drug Addiction, 2010, 191 pp.
36.Meffre, C, et al. Prevalence of hepatitis B and C in France in 2004. Institut de veille sanitaire, Saint-Maurice, March 2007, 114 pp.
37.Desenclos, JC, Costagliola, D, Commenges, D, et al. Prevalence of HIV infection in France. Bulletin Epidémiologique Hebdomadaire 2005; 11: 41–44.
38.OFDT.Drugs and dependence: indicators and trends of the French Drug Abuse Observatory, 1999. French Observatory for Drugs and Drug Addiction.
39.Emmanuelli, J, Jauffret-Roustide, M, Barin, F. Epidemiology of HCV infection among drug users, France, 1993–2002. Bulletin Epidémiologique Hebdomadaire 2003; 16–17: 13–15.
40.Jauffret-Roustide, M, et al. Estimate of HIV and HCV prevalence and patterns of drug users in France, InVS-ANRS Coquelicot study, 2004. Bulletin Epidémiologique Hebdomadaire 2006; 33: 244–247.
41.Emmanuelli, J, Desenclos, JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 2005; 100: 1690–1700.
42.Delarocque-Astagneau, E, et al. The hepatitis C surveillance system committee and the scientific committee for the national prevalence survey of hepatitis B and C markers. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. Journal of Viral Hepatitis 2010; 17: 435–443.
43.Cadet-Tairou, A, et al. Health status of drug users. Drugs and drug use in France. Levels of use and recent trends 2007–2009. Ninth Edition of the National Report of the TREND system. French Observatory for Drugs and Drug Addiction (OFDT), 2010.
44.Jauffret-Roustide, M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data-the ANRS-Coquelicot Study. Substance Use and Misuse 2006; 41: 1603–1621.
45.Van Den Berg, CH, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. European Journal of Epidemiology 2007; 22: 183–193.
46.Bello, PY, Cadet-Tairou, A, Halfen, S. Health status of problem drug users. Drugs and drug use in France. Illicit drug uses in France since 1999 from the TREND system. French Observatory for Drugs and Drug Addiction (OFDT), 2010.
48.Dubois-Arber, F, et al. Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993–2006. Eurosurveillance 2008; 13: 18881.
49.Schmitt, C, Bertel, J, Jacob, C. Incidence of serological markers of hepatitis B and C viruses and HIV in a population of drug abusers hospitalized from 1990 to 1992. Annales de Médecine Interne 1994; 145: 7–12.
50.Aaron, S, et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clinical Infectious Diseases 2008; 47: 931–934.
51.Lettmeier, B, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. Journal of Hepatology 2008; 49: 528–536.
52.Bruggmann, P, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. Journal of Viral Hepatitis 2008; 15: 747–752.
53.Chossegros, P, et al. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. Gastroentérologie Clinique et Biologique 2008; 32: 850–857.
54.Moussalli, J, et al. Management of hepatitis C among drug user patients. Gastroentérologie Clinique et Biologique 2007; 31: 4S51–4S55.
55.Backmund, M, et al. Treatment of hepatitis C infection in drug users. Hepatology 2001; 34: 188–193.
56.Sylvestre, DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence 2002; 67: 117–123.
57.Dalgard, O, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. European Addiction Research 2002; 8: 45–49.